Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company aiming for profitability soon. Analysts project it to break even in 2025 with a 63% annual growth rate. The absence of debt reduces investment risk. For detailed analysis, visit Simply Wall St.